Chlamydia trachomatis DNA vaccine - University of Manitoba

Drug Profile

Chlamydia trachomatis DNA vaccine - University of Manitoba

Latest Information Update: 30 Apr 2002

Price : $50

At a glance

  • Originator Nonindustrial source
  • Class Bacterial vaccines; DNA vaccines; Gene therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Chlamydial infections

Most Recent Events

  • 21 Aug 2000 A preclinical study has been added to the Bacterial Infections pharmacodynamics section
  • 13 Jun 2000 A preclinical study has been added to the Bacterial Infections pharmacodynamics section
  • 08 Oct 1997 Preclinical development for Chlamydial infections in Canada (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top